Reply: Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?

Abstract

Get full access to this article

View all access options for this article.

References

Cheng

JWM

Colucci

Kalus

Spinler

. Managing diabetes and preventing heart disease: have we found a safe and effective agent? Ann Pharmacother. 2019;53:510-522. doi:10.1177/1060028018816466

Reeder

Gilbert

Moran

. Comment: managing diabetes and preventing heart disease: have we found a safe and effective agent? Ann Pharmacother. 2019;53:1071.

Boehringer

Ingelheim

. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with reduced ejection fraction (EMPEROR-Reduced). https://clinicaltrials.gov/ct2/show/NCT03057977. Published February 20, 2017. Accessed June 20, 2019.

Boehringer

Ingelheim

. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt failure with preserved ejection fraction (EMPEROR-Preserved). https://clinicaltrials.gov/ct2/show/NCT03057951. Published February 20, 2017. Accessed June 20, 2019.

AstraZeneca . Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure (DAPA-HF). https://clinicaltrials.gov/ct2/show/NCT03036124. Published January 30, 2017. Accessed June 20, 2019.